Clinical Guidelines for Maternal Neurologic Disorders

Abstract

Maternal neurologic disorders present unique challenges in obstetric care, requiring an intricate balance between maternal well-being and fetal safety. This review synthesizes current clinical guidelines, recent advances, and evidence-based recommendations for the diagnosis, management, and follow-up of neurologic conditions during pregnancy. By focusing on epidemiology, pathophysiology, risk stratification, and contemporary management strategies, the article aims to provide healthcare professionals with practical insights for optimizing maternal and fetal outcomes in this vulnerable population.

Introduction

Neurologic disorders in pregnancy span a broad spectrum, including pre-existing conditions such as epilepsy, migraine, multiple sclerosis, and acute events like stroke or eclampsia. These disorders can significantly impact maternal and fetal morbidity and mortality. Effective management requires a multidisciplinary approach, adherence to up-to-date clinical practice guidelines, and individualized care plans that address the dynamic physiological changes of pregnancy. This review delineates the current scientific understanding and guideline-based recommendations for managing maternal neurologic disorders, emphasizing recent evidence and clinical implications.

Epidemiology / Disease Burden

Neurologic disorders complicate approximately 0.2–2% of pregnancies, with epilepsy being the most prevalent chronic neurologic condition. The incidence and prevalence of neurologic complications such as stroke, transient ischemic attack, and eclampsia are rising, partly due to maternal age trends and comorbidities. Migraine affects up to 20% of women of childbearing age, and its course during pregnancy is unpredictable. The disease burden is compounded by diagnostic challenges and the need for teratogen avoidance in pharmacologic therapy, highlighting significant implications for maternal health systems globally.

Pathophysiology

Pregnancy induces profound physiologic and hormonal changes that influence the course and presentation of neurologic disorders. Increased blood volume, coagulability, and vascular permeability heighten the risk for cerebrovascular events. Hormonal fluctuations can alter seizure threshold, migraine activity, and immune responses, affecting conditions such as multiple sclerosis. Placental hormones, altered drug pharmacokinetics, and increased metabolic demands further complicate pathogenesis and disease trajectory in pregnant women with underlying neurologic disease.

Risk Factors

Key risk factors for maternal neurologic disorders include advanced maternal age, hypertension, preeclampsia, thrombophilia, prior neurologic events (e.g., stroke, TIA), autoimmune diseases, and family history of neurologic illness. Certain genetic predispositions, medication non-adherence, and comorbidities such as diabetes and obesity also increase risk. Socioeconomic disparities and inadequate prenatal care may delay diagnosis and exacerbate outcomes.

Clinical Features

Clinical presentations vary widely, from headache, visual disturbances, seizures, and focal neurologic deficits to altered mental status and coma. Migraine typically presents as recurrent, throbbing headaches with or without aura. Epilepsy is characterized by tonic-clonic or focal seizures; changes in frequency can signal metabolic or pharmacologic issues. Eclampsia presents with new-onset seizures and hypertension after 20 weeks gestation. Acute neurologic deficits may signal stroke or central venous thrombosis, necessitating rapid evaluation.

Diagnosis

Diagnosis is guided by clinical suspicion, detailed history, and targeted neurologic examination. Imaging modalities, such as MRI (preferred over CT due to lack of ionizing radiation), are employed for acute presentations. EEG is indicated for seizure activity, while laboratory studies assess metabolic, hematologic, and infectious etiologies. Diagnostic strategies must minimize fetal risk; gadolinium-based contrast and teratogenic agents are generally avoided unless benefits outweigh risks. Multidisciplinary input is crucial for complex cases.

Treatment & Management

Management is individualized, balancing maternal neurologic control and fetal safety. For epilepsy, monotherapy with the lowest effective dose of pregnancy-compatible antiepileptic drugs (AEDs), such as lamotrigine or levetiracetam, is preferred. Preconception counseling and folic acid supplementation are recommended. Migraine management prioritizes non-pharmacologic strategies; acetaminophen is first-line, while triptans and NSAIDs are used cautiously. Acute stroke requires rapid reperfusion therapy, thrombectomy, and supportive care, with careful consideration of anticoagulant safety. Eclampsia mandates magnesium sulfate for seizure prophylaxis and expedited delivery. Multiple sclerosis management may involve suspension or adaptation of disease-modifying therapies during pregnancy and postpartum, guided by relapse risk and breastfeeding considerations.

Recent Advances / Emerging Therapies

Recent advances include the development of newer, safer AEDs and migraine therapies with favorable reproductive safety profiles. Monoclonal antibodies targeting CGRP in migraine show promise but require further safety data. Non-invasive neuromodulation and telemedicine have improved access to specialist care. Enhanced risk stratification tools and biomarkers are being explored for early identification of women at high risk for stroke or eclampsia. Multicenter registries and real-world data are refining safety profiles for neurologic medications in pregnancy.

Guideline Recommendations

Current guidelines from ACOG, AAN, and international neurology societies emphasize preconception counseling, individualized risk assessment, and multidisciplinary management. AEDs should be selected based on efficacy and teratogenic risk; therapeutic drug monitoring is advised due to altered pharmacokinetics in pregnancy. Imaging should not be delayed in acute neurologic events. Early identification and treatment of hypertensive disorders are paramount in preventing eclampsia. Breastfeeding is generally encouraged, except where drug safety is uncertain. Postpartum follow-up is vital for relapse prevention and long-term neurologic health.

Conclusion

Maternal neurologic disorders demand vigilant, evidence-based care that integrates guideline recommendations, recent advances, and individualized risk-benefit assessments. Clinicians must maintain a high index of suspicion, coordinate multidisciplinary interventions, and prioritize both maternal and fetal outcomes. Ongoing research and evolving guidelines continue to inform best practices, underscoring the importance of continual professional education and patient-centered management in this rapidly advancing field.